Immunization with DnaJ (hsp40) could elicit protection against nasopharyngeal colonization and invasive infection caused by different strains of Streptococcus pneumoniae

被引：40

作者：

Cui, Yali ^{[2
]}

Zhang, Xuemei ^{[2
]}

Gong, Yi ^{[2
]}

Niu, Siqiang ^{[2
]}

Yin, Nanlin ^{[2
]}

Yao, Run ^{[2
]}

Xu, Wenchun ^{[2
]}

Li, Dairong ^{[1
]}

Wang, Hong ^{[2
]}

He, Yujuan ^{[2
]}

Cao, Ju ^{[1
]}

Yin, Yibing ^{[2
]}

机构：

[1] Chongqing Med Univ, Affiliated Hosp 1, Dept Lab Med, Chongqing, Peoples R China

[2] Chongqing Med Univ, Dept Lab Med, Minist Educ, Key Lab Diagnost Med Designated, Chongqing, Peoples R China

来源：

VACCINE | 2011年 / 29卷 / 09期

关键词：

DnaJ; Immunization; Vaccine; Streptococcus pneumoniae; PNEUMOCOCCAL CONJUGATE VACCINES; SURFACE PROTEIN-A; MUCOSAL IMMUNIZATION; IMMUNE-RESPONSE; UNITED-STATES; MICE; VACCINATION; DISEASE; DIVERSITY; PSPA;

D O I：

10.1016/j.vaccine.2010.12.126

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Increasing mortality, morbidity and economic costs have been paid to pneumococcal diseases every year. Currently, vaccination is the most promising strategy to reduce the occurrence of pneumococcal infection. In this study, we investigated the protective efficacy of immunization with recombinant DnaJ (hsp40) protein against infections of different serotypes of Streptococcus pneumoniae. We demonstrated that mucosal immunization with DnaJ antigen could induce both systemic and mucosal antibodies for DnaJ and stimulate the release of high levels of IL-10, IFN-gamma and IL-17A. Moreover, this mucosal vaccination could reduce nasal or lung colonization of pneumococcus and elicit protection against different serotypes of invasive pneumococcal infections. As well, we found that intraperitoneal immunization with DnaJ could also protect against invasive infections caused by different serotypes of pneumococcus, and passive immunization with antibodies specific for DnaJ confirmed that this protection was antibody-mediated. Our results therefore support the potential of DnaJ as a conserved pneumococcal protein vaccine. (C) 2011 Elsevier Ltd. All rights reserved.

引用

页码：1736 / 1744

页数：9

共 47 条

[11]

[12] CONSTRUCTION AND EVALUATION OF NEW DRUG-RESISTANCE CASSETTES FOR GENE DISRUPTION MUTAGENESIS IN STREPTOCOCCUS-PNEUMONIAE, USING AN AMI TEST PLATFORM [J].

CLAVERYS, JP ;

DINTILHAC, A ;

PESTOVA, EV ;

MARTIN, B ;

MORRISON, DA .

GENE, 1995, 164 (01) :123-128

[13]

DELGIUDICE G, 1994, EXPERIENTIA, V50, P1061

[14] Immunogenicity of pneumococcal conjugate vaccines [J].

Eskola, J .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2000, 19 (04) :388-393

[15] The clinical effectiveness of pneumococcal vaccination: a brief review [J].

Fedson, DS .

VACCINE, 1999, 17 :S85-S90

[16] Characterization of Protective Mucosal and Systemic Immune Responses Elicited by Pneumococcal Surface Protein PspA and PspC Nasal Vaccines against a Respiratory Pneumococcal Challenge in Mice [J].

Ferreira, D. M. ;

Darrieux, M. ;

Silva, D. A. ;

Leite, L. C. C. ;

Ferreira, J. M. C., Jr. ;

Ho, P. L. ;

Miyaji, E. N. ;

Oliveira, M. L. S. .

CLINICAL AND VACCINE IMMUNOLOGY, 2009, 16 (05) :636-645

[17] Optimized immune response elicited by a DNA vaccine expressing pneumococcal surface protein a is characterized by a balanced immunoglobulin G1 (IgG1)/IgG2a ratio and proinflammatory cytokine production [J].

Ferreira, Daniela M. ;

Darrieux, Michelle ;

Oliveira, Maria Leonor S. ;

Leite, Luciana C. C. ;

Miyaji, Eliane N. .

CLINICAL AND VACCINE IMMUNOLOGY, 2008, 15 (03) :499-505

[18] Discovery of a novel class of highly conserved vaccine antigens using genomic scale antigenic fingerprinting of pneumococcus with human antibodies [J].

Giefing, Carmen ;

Meinke, Andreas L. ;

Hanner, Markus ;

Henics, Tamas ;

Minh, Duc Bui ;

Gelbmann, Dieter ;

Lundberg, Urban ;

Senn, Beatrice M. ;

Schunn, Michael ;

Habel, Andre ;

Henriques-Normark, Birgitta ;

Oetqvist, Ake ;

Kalin, Mats ;

von Gabain, Alexander ;

Nagy, Eszter .

JOURNAL OF EXPERIMENTAL MEDICINE, 2008, 205 (01) :117-131

[19] Relationship between surface accessibility for PpmA, PsaA, and PspA and antibody-mediated immunity to systemic infection by Streptococcus pneumoniae [J].

Gor, DO ;

Ding, XD ;

Briles, DE ;

Jacobs, MR ;

Greenspan, NS .

INFECTION AND IMMUNITY, 2005, 73 (03) :1304-1312

[20] Preventability of invasive pneumococcal disease and assessment of current polysaccharide vaccine recommendations for adults: United States, 2001-2003 [J].

Greene, Carolyn M. ;

Kyaw, Moe H. ;

Ray, Susan M. ;

Schaffner, William ;

Lynfield, Ruth ;

Barrett, Nancy L. ;

Long, Christine ;

Gershman, Ken ;

Pilishvili, Tamar ;

Roberson, Angela ;

Zell, Elizabeth R. ;

Whitney, Cynthia G. ;

Bennett, Nancy M. .

CLINICAL INFECTIOUS DISEASES, 2006, 43 (02) :141-150

← 1 2 3 4 5 →